News and Press Releases
Press releases
Theralase® Technology Effective in Virus Inactivation
Press ReleaseJune 4, 2024 - Theralase's lead compound, Ruvidar, has been proven effective in the inactivation of various viruses. The research was completed at the laboratory of Kevin Coombs, Ph.D., University of Manitoba in conjunction with...
Theralase® Release’s 1Q2024 Financial Statements
Press ReleaseMay 30, 2024 - Theralase releases the Company's unaudited interim consolidated 1Q2024 Financial Statements...
Theralase® Expands Clinical Team
Press ReleaseMay 2, 2024 - Theralase expands its clinical team with the hiring of two Clinical Research Associates....
Theralase® Closes $CAN 750,000 Non-Brokered Private Placement
Press ReleaseApril 24, 2024 - Theralase closes Non-Brokered Private Placement of units for gross proceeds of $CAN 750,200....
Theralase® Granted Canadian Cancer Vaccine Patent
Press ReleaseApril 5th, 2024, Theralase® granted Canadian patent for a new cancer vaccine titled, “Vaccine Containing Cancer Cells Inactivated by Photodynamic Treatment with Metal-Based Coordination Complexes and Immunotherapy Method Using Same”....
Theralase® Release’s 4Q2023 Interim Financial Statements
Press ReleaseMarch 27, 2024 - Theralase released the Company’s audited annual consolidated 2023 financial statements (“Financial Statements”)....
Theralase® to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
Press ReleaseV.TLT | March 26th, 2024 Toronto, Ontario – March 26th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and develo...
Theralase® Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson’s Disease
Press ReleaseV.TLT | February 12th, 2024 Toronto, Ontario – February 12th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and developm...
Dr. Michael Jewett Joins Theralase® to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleaseV.TLT | February 8th, 2024 Toronto, Ontario – February 8th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and developmen...
Theralase® Closes $CAN 1.2 Million Non-Brokered Private Placement
Press ReleaseV.TLT | February 5th, 2024 Toronto, Ontario – February 5th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and developmen...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
